InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (8 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
8
T+90 hit rate
0%
T+90 mean return
-47.5%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Foody Joanne M., Directeur Médical. Officer active across 1 company, notably Esperion Therapeutics, Inc.. In total, 15 reports have been recorded. Breakdown: 0 buy · 8 sells. Total volume traded: €77k. Activity tracked since 28 June 2021. The latest transaction was disclosed on 17 July 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations15 total
917 shares@ US$2.5992.8% of flowCommon StockSEC:0001628280-24-032267:0
3,285 shares@ US$2.86711.4% of flowCommon StockSEC:0001628280-24-029116:0
150,000 shares0Common StockSEC:0001628280-24-011492:0
938 shares@ US$1.2711.4% of flowCommon StockSEC:0001628280-23-012263:0
3,808 shares@ US$1.78198.3% of flowCommon StockSEC:0001628280-23-008613:0
28,750 shares0Common StockSEC:0001628280-23-007967:0
3,884 shares@ US$5.06523.9% of flowCommon StockSEC:0001628280-23-006989:0
1,191 shares@ US$6.98510.0% of flowCommon StockSEC:0001628280-23-001277:0
942 shares@ US$7.6889.6% of flowCommon StockSEC:0001628280-22-026633:0
3,901 shares@ US$6.5532.5% of flowCommon StockSEC:0001628280-22-019180:0
28,000 shares0Common StockSEC:0001628280-22-006409:0
22,450 shares0Common StockSEC:0001628280-21-021007:0
22,450 shares0Common StockSEC:0001628280-21-021007
62,528 shares0Common StockSEC:0001628280-21-013634:0
62,528 shares0Common StockSEC:0001628280-21-013634
15 of 15 declarations
About Foody Joanne M.
Joanne M. Foody serves as Chief Medical Officer at Esperion Therapeutics, Inc. In this role, she is responsible for leading the company's clinical initiatives and medical research. Joanne M. Foody plays a vital role in developing new treatments and improving patient care. Her medical expertise is crucial to Esperion's mission of transforming the management of cardiovascular diseases.
